---
title: First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations.
euct_id: 2023-509158-68-00
phase: Phase 1
status: Recruiting
sponsor: Vanqua Bio Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2023-509158-68-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2023-509158-68-00"
ctis_last_updated: "2025-09-25T03:40:07.869370189"
source: EU Clinical Trials Information System (CTIS)
---
# First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations.

**EU CT Number:** [2023-509158-68-00](https://euclinicaltrials.eu/ctis-public/view/2023-509158-68-00)

## Key Facts

- **Phase:** Phase 1
- **Status:** Recruiting
- **Sponsor:** Vanqua Bio Inc.
- **Start Date:** 2024-01-20
- **Completion Date:** 2026-08-31
- **Conditions:** Parkinson’s disease

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (2)

- Pharmaceutical Research Associates Group B.V., Groningen, Netherlands
- Centre for Human Drug Research, Leiden, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s disease
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2023-509158-68-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2023-509158-68-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2023-509158-68-00*